Summary of Jade Biosciences Conference Call Company Overview - Jade Biosciences is a recently formed company focused on autoimmune diseases, established in June 2024, with significant progress made in a short time frame [3][4] - The company has access to three assets from Paragon, which are pivotal for its development strategy [3] Core Products and Pipeline - **Lead Program: JADE101** - An anti-APRIL monoclonal antibody targeting IgA nephropathy (IgAN), currently in phase one trials with expected readout in the next quarter [5][6] - Aims to be a best-in-class therapeutic with disease-modifying potential, including stabilizing eGFR [5] - Designed for high-affinity binding (50 femtomolar), significantly higher than competitors, allowing for rapid and sustained APRIL neutralization [11][14] - Expected to have a dosing interval of Q8 weeks, significantly reducing patient burden compared to existing therapies [18][27] - **Second Program: JADE201** - A half-life extended anti-BAFF-R monoclonal antibody, targeting various autoimmune diseases, with a phase one trial planned in rheumatoid arthritis [45][48] - Aims to retain the pharmacological properties of Ianalumab while providing a more durable receptor occupancy [46] Market Opportunity - The U.S. market for IgAN is estimated to exceed $20 billion, driven by the growing number of treatment-eligible patients and the pricing strategy of competitors [25][26] - Jade Biosciences believes that the anti-APRIL class will dominate this market due to its efficacy and convenience [26][27] Competitive Landscape - The company positions itself against competitors like Otsuka's sibeprenlimab, which has shown similar efficacy but with a less favorable dosing regimen [22][24] - Data from Vertex's recent trials suggest that APRIL is a key driver in IgAN, reinforcing Jade's focus on selective APRIL inhibition [22][24] Clinical Development and Regulatory Strategy - The company plans to initiate a phase 2 trial for JADE101 around mid-2026, leveraging insights from the phase 1 study [33][34] - Regulatory discussions are ongoing to potentially streamline the approval process for new therapies in IgAN, which could benefit Jade's development timeline [36] Safety and Efficacy Considerations - Selective APRIL inhibition is believed to provide significant disease-modifying effects without the broader immunosuppressive risks associated with BAFF inhibition [19][20] - The company aims to demonstrate superior safety profiles compared to dual inhibitors, which have not shown additional clinical benefits [20][21] Future Directions - Jade Biosciences is exploring potential applications for anti-APRIL therapies beyond IgAN, including IgM-mediated diseases and Sjögren's syndrome [42][43] - The company is committed to monitoring the competitive landscape and adjusting its strategy based on emerging data and market needs [44] Key Takeaways - Jade Biosciences is positioned to capture a significant share of the IgAN market with its innovative therapies and strategic focus on patient convenience and efficacy [26][27] - The upcoming clinical data and regulatory developments will be crucial in shaping the company's future trajectory and market positioning [29][36]

Summary of Cullinan Therapeutics Conference Call Company Overview - **Company**: Cullinan Therapeutics - **Key Personnel**: Nadim Ahmed (President and CEO), Jeff Jones (CMO) - **Event**: 46th Annual TD Cowen Healthcare Conference Key Milestones and Programs - **Transformational Year**: 2026 is anticipated to be a pivotal year for Cullinan Therapeutics with multiple catalysts and milestones across programs [2] - **Key Programs**: - **CLN-978**: A CD19 by CD3 T-cell engager targeting autoimmune diseases, with potential to be best in class. Development studies are ongoing in rheumatoid arthritis (RA), lupus, and Sjögren's disease, with initial data expected in Q2 2023 [2][3] - **CLN-049**: A FLT3 by CD3 bispecific T-cell engager for acute myeloid leukemia (AML), presenting a first-in-class immunotherapeutic approach. Promising monotherapy efficacy data was presented at ASH [4][34] Clinical Development Insights - **CLN-978**: - High affinity for CD19 and small molecular size may enhance tissue penetration and allow for subcutaneous administration [3] - Initial clinical data for RA and lupus expected in Q2 2023, with multi-dose data for RA in Q3 and Sjögren's disease data in Q4 [3][14] - The potential for treatment-free remissions is highlighted as a significant advantage over current therapies [6][24] - **CLN-049**: - Achieved a composite complete response (CR) rate of 31% at the highest dose tested (12 micrograms per kilogram), competitive with recent AML approvals [34] - The absence of biomarkers predicting response suggests a novel all-comer immunotherapy approach [35][38] Safety and Efficacy Considerations - **Safety Profile**: - Aim to minimize the rate of grade 2 cytokine release syndrome (CRS) to 10% or less, with grade 1 CRS being manageable [21][22] - Focus on preventing neurotoxicity, particularly immune effector cell-associated neurotoxicity syndrome (ICANS) [22] - **Efficacy Expectations**: - For CLN-978, achieving dose-dependent B-cell depletion and acceptable safety is critical for initial data [19][20] - For CLN-049, a response rate of 20% in patients with P53 mutations is considered clinically meaningful [41] Development Pathway - **Regulatory Strategy**: - Plans for accelerated development in specific subsets of autoimmune diseases if compelling efficacy and safety are demonstrated [28] - A systematic dose-finding regimen is being employed across multiple indications to streamline development [30] - **Future Updates**: - Data updates expected in Q2 2023, with ongoing dose escalation and expansion phases planned for later in the year [53][55] Market Context - **Industry Trends**: - The T-cell redirecting therapy space is gaining traction, with recent acquisitions indicating strong interest [4] - The standard of care in AML has remained stagnant, highlighting the need for innovative therapies like CLN-049 [33] Conclusion Cullinan Therapeutics is positioned for significant advancements in 2026, with promising data expected from its key programs CLN-978 and CLN-049. The focus on safety, efficacy, and a clear regulatory pathway will be crucial in navigating the competitive landscape of autoimmune diseases and AML therapies.

Core Insights - GSK plc reported fourth-quarter 2025 core earnings of 68 cents per American depositary share (ADS), exceeding the Zacks Consensus Estimate of 64 cents, with a 10% year-over-year increase on a reported basis and 14% at a constant exchange rate (CER) [1][9] - Quarterly revenues rose 6% on a reported basis and 8% at CER to $11.46 billion (£8.62 billion), driven by increased sales of HIV, oncology, and respiratory medicines, surpassing the Zacks Consensus Estimate of $11.19 billion [2][9] Segment Performance - GSK operates under three segments: General Medicines, Specialty Medicines, and Vaccines. Specialty Medicines sales increased by 18%, while Vaccine sales rose by 4%. General Medicines sales fell by 1% [3] - Specialty Medicines drove top-line growth, with HIV sales up 11% due to increased demand for Dovato and long-acting medications like Apretude and Cabenuva [4][5] - Oncology sales surged by 42%, primarily due to strong demand for Jemperli and Ojjaara/Omjjara, with Jemperli sales increasing by 79% following label expansion [6][7] - Respiratory drug Nucala sales rose by 19%, driven by strong performance in the U.S. market, while Benlysta sales increased by 26% [8] Vaccine Sales - GSK's vaccine sales growth was driven by increased uptake of meningitis, RSV, and shingles vaccines in ex-U.S. markets, with Shingrix sales rising by 20% [10] - Established vaccine sales declined by 13% due to divested brands and lower sales for Rotarix and Synflorix [11] General Medicines - General Medicines showed stable performance with Trelegy Ellipta sales up 14%, while Anoro Ellipta and Relvar/Breo Ellipta sales fell by 10% and 16%, respectively [12][13] Operating Expenses and Guidance - Core selling, general, and administration costs rose by 2% to £2.68 billion, while core research and development expenses increased by 18% to £2.12 billion [14] - GSK expects sales growth of 3-5% in 2026, with specialty medicines projected to grow by a low double-digit percentage at CER [15] Future Outlook - GSK has a total of 58 assets in clinical development, with two major product approvals expected this year [21][22] - The company aims to generate sales of more than £40 billion by 2031, reflecting a positive long-term outlook [18]

Core Insights - GSK reported a strong performance in 2025 with sales growth of 7% at constant exchange rates, reaching over £32 billion, and core operating profit increasing by 11% [3][6] - The company emphasized its focus on specialty medicines, which saw a significant increase of 17%, driven by respiratory, oncology, and HIV segments [5][9] - GSK's guidance for 2026 includes sales growth of 3-5% and core operating profit and EPS growth of 7-9%, alongside a proposed dividend increase of 6% to £0.70 [6][7] Financial Performance - Free cash flow rose to £4.0 billion, with £1.2 billion in Zantac payments expected in 2025, and total shareholder distributions of £4.0 billion through dividends and buybacks [1][3] - Operating margin improved by 110 basis points to 29.9%, driven by better SG&A margins and a shift towards specialty medicines [2][6] - Cash generated from operations was £8.9 billion, supporting investments and a dividend increase of 2p to 66p [3][6] Commercial and Pipeline Developments - Specialty medicines are expected to continue growing at a low double-digit percentage, with HIV products showing mid- to high single-digit growth [7][8] - The company highlighted the importance of upcoming product launches, particularly Extensa and Blenrep, with a focus on execution in 2026 [14][15] - GSK secured five FDA approvals in 2025 and initiated seven new pivotal trials, indicating a robust pipeline and commitment to accelerating development timelines [17][18] Market Trends and Strategic Focus - The company is experiencing broad-based sales growth across all regions, with notable increases in respiratory (18%), oncology (43%), and HIV (11%) segments [9][12][11] - GSK's management is prioritizing business development and simplifying operations while increasing the use of technology such as AI [4][19] - The planned acquisition of RAPT Therapeutics aims to advance the development of Ozuriquibat, a long-acting anti-IgE monoclonal antibody [19]

Financial Data and Key Metrics Changes - Sales increased by 7% to over GBP 32 billion, driven by Specialty Medicines which grew by 17% [2][5] - Core operating profit grew by 11%, and EPS was up by 12% [2][29] - Cash generation was strong at GBP 8.9 billion, supporting future investments and enabling a dividend upgrade of 2p to 66 pence [2][29] - Operating margin increased by 110 basis points, with total accretion at CER reaching 470 basis points over the last four years [30] Business Line Data and Key Metrics Changes - Specialty Medicines sales were up 17%, with significant contributions from respiratory immunology and oncology [5][6] - Respiratory immunology and inflammation sales increased by 18%, driven by Benlysta and Nucala [5][6] - Oncology sales surged by 43%, with Jemperli sales up by 89% [6][7] - HIV sales grew by 11%, with long-acting injectables driving over 75% of growth [10][11] Market Data and Key Metrics Changes - Nucala achieved 10 consecutive years of double-digit growth, with sales reaching GBP 2 billion [6] - Shingrix sales were GBP 3.6 billion, up 8%, driven by European and international markets [15] - Bexsero sales increased by 12%, with strong growth in Europe and international markets [15][16] - The U.S. market for long-acting HIV treatments is expected to grow significantly, with Cabenuva growing by 42% [10][11] Company Strategy and Development Direction - The company aims to drive top-line growth by maximizing launch products and accelerating key assets in late-stage portfolios [3][4] - There is a focus on simplifying operations and leveraging AI and technology to enhance productivity [4] - The company is committed to evolving its product-centric approach and accelerating its pipeline through smart business development [37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another year of profitable growth in 2026, with guidance for sales growth of 3%-5% and core operating profit growth of 7%-9% [32][34] - The company anticipates challenges from currency fluctuations and pricing pressures but remains optimistic about its long-term growth trajectory [34][35] - Management highlighted the importance of long-acting treatments in the HIV market and the potential for significant market share gains [10][11] Other Important Information - The company announced a strategic acquisition of RAPT Therapeutics to enhance its pipeline in food allergy treatments [27] - The transition to long-acting regimens in HIV care is expected to redefine treatment paradigms and expand market opportunities [12][13] Q&A Session Summary Question: Can you elaborate on R&D commercial strategy in COPD and asthma? - Management discussed the positioning of various products in the COPD and asthma markets, emphasizing the complexity of the disease and the need for a diverse portfolio [39][42] Question: When could we see the six-monthly treatment and what is the TAM increase? - Management confirmed that the six-monthly treatment regimen is on track for phase 2B trials this year, with significant market potential anticipated [48][49] Question: Update on the launch trajectory for Blenrep? - Initial feedback indicated a slow but positive ramp-up for Blenrep, with a focus on educating eye care professionals and ensuring a positive experience for patients [59][66]

Financial Data and Key Metrics Changes - Sales increased by 7% to over GBP 32 billion, driven by Specialty Medicines which grew by 17% [2][5] - Core operating profit grew by 11%, and EPS was up by 12% [2][29] - Cash generation was strong at GBP 8.9 billion, supporting future investments and enabling a dividend increase of 2p to 66 pence [2][29] - Operating margin increased by 110 basis points, with total accretion at CER reaching 470 basis points over the last four years [30] Business Line Data and Key Metrics Changes - Specialty Medicines sales were up 17%, with significant contributions from respiratory immunology and oncology [5][6] - Respiratory immunology and inflammation sales increased by 18%, driven by Benlysta and Nucala [5][6] - Oncology sales surged by 43%, with Jemperli sales up by 89% [6][7] - Vaccine sales were GBP 9.2 billion, up 2%, with Shingrix and Bexsero driving growth [15][16] Market Data and Key Metrics Changes - Nucala achieved 10 consecutive years of double-digit growth, with sales reaching GBP 2 billion [6] - The U.S. market for HIV treatment grew by 14%, with long-acting injectables contributing significantly to sales [10][11] - Ex-U.S. markets represented 69% of Bexsero's global sales, indicating strong international demand [16] Company Strategy and Development Direction - The company aims to drive top-line growth by maximizing product launches and accelerating key assets in late-stage portfolios [3][4] - A focus on simplifying operations and leveraging AI and technology to enhance efficiency [4] - The strategy includes a commitment to long-acting treatments in HIV, with plans for Q6M treatment regimens [12][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued profitable growth for 2026, with guidance for sales growth of 3%-5% and core operating profit growth of 7%-9% [32][34] - The company is navigating challenges such as currency headwinds and pricing pressures but remains optimistic about its pipeline and market position [34][36] - Management emphasized the importance of evolving the company to be more product-centric and agile in capitalizing on opportunities [37] Other Important Information - The company secured 5 FDA approvals and initiated 7 new pivotal trials in 2025 [18] - The acquisition of RAPT Therapeutics for Ozuriquimab, a long-acting anti-IgE monoclonal for food allergies, is expected to close soon [27] - The company is on track to deliver significant data readouts and pivotal starts in 2026, supporting growth in specialty medicines [28] Q&A Session Summary Question: Can you elaborate on R&D commercial strategy in COPD and asthma? - Management discussed the positioning of multiple products targeting different patient populations within COPD and asthma, emphasizing a strategic approach to avoid overlap [40][43] Question: When could we see the six-monthly treatment and what is the TAM increase? - Management confirmed that the Q6M treatment regimen is on track for phase IIb this year, with significant market potential for long-acting injectables in HIV treatment [49][50] Question: Can you update us on the launch trajectory for Blenrep? - Initial feedback indicated a slow but positive ramp-up for Blenrep, with a focus on educating eye care professionals and ensuring a positive experience for patients [59][63]

Financial Data and Key Metrics Changes - Sales increased by 7% to over GBP 32 billion, driven by Specialty Medicines which grew by 17% [2] - Core operating profit grew by 11%, and EPS was up by 12% [2] - Cash generation was strong at GBP 8.9 billion, supporting future investments and enabling a dividend upgrade to 66 pence [2][29] - Operating margin increased by 110 basis points, with total accretion at CER reaching 470 basis points over the last four years [30] - Cash generated from operations was GBP 8.9 billion, with free cash flow increasing to GBP 4 billion [31] Business Line Data and Key Metrics Changes - Specialty Medicines sales were up 17%, with significant contributions from respiratory immunology and inflammation, which saw an 18% increase [5] - Oncology sales surged by 43%, with Jemperli sales up by 89% [5][6] - HIV sales grew by 11%, driven by long-acting injectables and foundational oral regimens [9] - Vaccine sales were GBP 9.2 billion, up 2%, with Shingrix sales increasing by 8% [15] - GenMed sales slightly declined, with Trelegy showing strong growth offset by other respiratory products [17] Market Data and Key Metrics Changes - Nucala achieved 10 consecutive years of double-digit growth, with sales reaching GBP 2 billion [5] - The U.S. market for long-acting HIV treatments is projected to grow significantly, with Cabenuva growing by 42% [10] - Shingrix sales in Europe and international markets were strong, while U.S. sales faced challenges due to slowing immunization rates [15] - The U.S. retains a 74% market share in MenB vaccines, with positive signs for PenmenV [15] Company Strategy and Development Direction - The company aims to drive top-line growth by maximizing product launches and accelerating key assets in late-stage portfolios [3] - A focus on simplifying operations and leveraging AI and technology to enhance execution [4] - The strategy includes a commitment to long-acting treatments in HIV, with plans for Q6M treatment regimens [11][49] - Business development remains a core focus, with recent acquisitions aimed at enhancing the pipeline [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued profitable growth for 2026, with guidance for sales growth of 3%-5% and core operating profit growth of 7%-9% [32] - The company is positioned to navigate challenges such as the loss of exclusivity for dolutegravir and aims to evolve as a more product-centric organization [37] - Management highlighted the importance of scientific courage and agility in capitalizing on opportunities [37] Other Important Information - The company has secured 5 FDA approvals and initiated 7 new pivotal trials in 2025 [18] - The Zantac charge taken in 2024 impacted total results, but the settlement process is now materially complete [31] - The company plans to maintain a strong balance sheet with net debt to EBITDA stable at 1.3 times [32] Q&A Session Summary Question: Can you elaborate on R&D commercial strategy in COPD and asthma? - Management discussed the positioning of Nucala, Extensa, and other products in the COPD and asthma markets, emphasizing a strategic approach to address different patient populations [40][43] Question: When could we see the six-monthly treatment and what is the TAM increase? - Management confirmed that Q6M treatment is on track for phase 2B this year, with a significant addressable market for long-acting injectables in HIV treatment [49][51] Question: Update on the launch trajectory for Blenrep? - Initial feedback on Blenrep's launch has been positive, with a systematic opening of accounts and engagement with eye care professionals [58][66] Question: Is the reduction in R&D staff part of a broader program? - Management clarified that the reduction is part of a dynamic approach to resource allocation, focusing on areas with the best return potential [72] Question: How should we think about the launch curve for Extensa? - Management indicated a focus on bio-naive patients for Extensa, aiming to broaden the market and improve patient retention [72]

Summary of Jade Biosciences Conference Call Company Overview - **Company**: Jade Biosciences (NasdaqCM:JBIO) - **Founded**: June 2024 - **Management Team**: Includes experienced members from Chinook Therapeutics, focusing on iGAN (IgA nephropathy) and autoimmune diseases - **Assets**: Three key assets acquired from Paragon, a protein engineering company Industry and Market Insights - **Lead Program**: Anti-APRIL for IgA nephropathy, a significant unmet medical need with a market opportunity exceeding $10 billion in the US alone [2] - **Clinical Development**: Initiated a Phase I study in August 2025, with results expected in the first half of 2026, aiming for rapid transition to patient studies [2][3] Key Programs and Developments - **JADE201**: A eufucosylated antibody targeting BAFF-R, expected to enter clinical trials in the first half of 2026 [2][3] - **Third Program**: Details not disclosed, anticipated to enter trials in the first half of 2027 [3] - **Financial Position**: Strong resources to fund trials through the first half of 2028 [3] Clinical Data and Efficacy - **ASN Conference Insights**: - iGAN is emerging as a large prospective market with promising data from competitors like Vera and Vertex [5][6] - Vertex reported a 64% reduction in proteinuria in Phase II studies, while Vera showed a 42% placebo-adjusted reduction [6] - Sibeprenlimab data indicated a 54% decrease in proteinuria over 12 months, highlighting the importance of APRIL inhibition [7][8] Mechanism of Action and Therapeutic Window - **APRIL vs. BAFF**: - Evidence suggests that APRIL inhibition alone provides significant disease-modifying benefits in iGAN without the need for BAFF [10][11] - Adding BAFF does not enhance clinical outcomes, indicating that iGAN is primarily driven by APRIL-responsive plasma cells [10][11] Regulatory Landscape - **FDA Considerations**: - The FDA is exploring new study designs to support innovation in iGAN, potentially shortening confirmatory study durations from two years to one year [30][31] - This shift is seen as beneficial for anti-APRIL therapies, which show early and significant eGFR improvements [30][31] Future Directions and Lifecycle Management - **Exploration of New Indications**: - Plans to investigate other autoimmune diseases, including IgM-mediated diseases and Sjogren's syndrome, based on the success of current programs [24][34] - JADE201's development will focus on generating safety and tolerability data in RA patients before expanding to other indications [34] Conclusion - Jade Biosciences is positioned to capitalize on significant market opportunities in the autoimmune disease space, particularly with its lead program targeting iGAN. The company is leveraging strong clinical data and a robust financial position to advance its pipeline and explore new therapeutic avenues.

Core Insights - The pharmaceutical industry is experiencing a structural change driven by the growth cycles of major products, with significant opportunities emerging in innovative drugs, medical devices, and consumer healthcare [3][6][31] - The demand for pharmaceuticals is expected to improve in 2026, supported by policies encouraging innovation and a recovery in domestic consumption [3][7] - The supply side of the pharmaceutical industry is characterized by high entry barriers due to patent protections and government regulations, which helps maintain a stable competitive environment [4][5] Group 1: Industry Trends - The aging population, urbanization, and changing disease patterns are making the pharmaceutical industry a perpetual growth sector [3] - The global pharmaceutical market has seen rapid expansion from 2009 to 2019, followed by a surge in demand due to COVID-19, and is now entering a phase of recovery and growth [3][6] - The Chinese pharmaceutical industry is expected to gradually produce world-class companies, with increasing recognition of Chinese innovative drug assets by multinational corporations (MNCs) [4][5] Group 2: Investment Opportunities - Opportunities in innovative drugs are highlighted, particularly in oncology, metabolic diseases, and autoimmune diseases, with a focus on next-generation therapies and precision medicine [6][31] - The demand for innovative drugs is expected to remain strong, with policies improving medical insurance payments and the upcoming launch of commercial insurance drug catalogs [7][31] - The medical device sector is anticipated to recover, with a focus on domestic demand and international expansion, particularly in areas with low domestic production rates [7][8] Group 3: Company Performance - Major pharmaceutical companies like Eli Lilly, AbbVie, and AstraZeneca are experiencing significant growth driven by key products, with Eli Lilly's Tirzepatide generating $24.8 billion in sales [12][15] - The report identifies specific companies such as Hengrui Medicine, Hansoh Pharmaceutical, and BeiGene as outperformers in the market, with strong pipelines and global competitiveness [7][8] - The report emphasizes the importance of mergers and acquisitions (M&A) and business development (BD) strategies for MNCs, with China becoming a significant source of projects for top global pharmaceutical companies [22][24]

Financial Data and Key Metrics Changes - Total sales increased by 8% for the quarter, with core operating profit up 11% and core earnings per share up 14% to 55p [3][4] - Cash generation for the year so far is £6.3 billion, supporting growth investments and shareholder returns, including a dividend of 16p for the quarter [4][36] - Operating margin improved by 90 basis points in the quarter, driven by SG&A margin improvement [38] Business Line Data and Key Metrics Changes - Specialty medicines sales grew by 16%, with significant contributions from oncology (up 39%) and respiratory immunology (up 15%) [10][12] - HIV portfolio delivered 12% growth, primarily driven by long-acting injectables [21] - Vaccine sales increased by 2%, with strong demand for Shingrix, particularly in Europe [29] Market Data and Key Metrics Changes - In the U.S., Shingrix penetration is now at 43% of the eligible older adult population, with international sales accounting for around 70% of global Shingrix sales [30] - The oncology portfolio is expected to be a material growth driver, with Glenrep approved in eight markets [16][18] Company Strategy and Development Direction - The company is focused on investing for growth, with a pipeline of 15 scale opportunities expected to launch before 2031 [5][7] - Continued emphasis on business development to expand the pipeline, particularly in oncology and respiratory [6][84] - The company is committed to optimizing supply capacity and investing $30 billion in R&D and advanced manufacturing in the U.S. over the next five years [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver on long-term commitments for growth, with an upgraded guidance for the year [8][42] - The company remains cautious about the near-term outlook for vaccines in the U.S. but is optimistic about long-term prospects [33] Other Important Information - The company has secured four FDA approvals this year and expects a fifth before year-end [4] - The company is upgrading its full-year sales expectations from 3-5% to 6-7% [42] Q&A Session Summary Question: Revenue gap between market expectations and GSK's target for 2031 - Management acknowledged the gap and highlighted underappreciated assets in oncology and respiratory as key areas for growth [51][54] Question: Future strategy updates - Management indicated that more details on the strategy would be provided at the full-year results, with confidence in achieving the £40 billion target by 2031 [52][58] Question: Shingrix growth expectations - Management confirmed that growth in Europe is expected to continue, with a focus on expanding immunization rates [60][66] Question: Investment in R&D and operational expenses - Management confirmed that R&D investment will continue to grow ahead of sales, with significant investments in new product launches [68] Question: Updates on Glenrep and Depamokimab - Management shared insights on the early experiences with Glenrep in Europe and the competitive landscape for Depamokimab, emphasizing the potential for both products [72][76]